No Data
No Data
Jefferies Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $92
Cytokinetics Insider Sold Shares Worth $410,638, According to a Recent SEC Filing
Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
Express News | Cytokinetics Inc : Jefferies Raises Target Price to $92 From $85
BioMarin Appoints New Business Chief and R&D Head
Cytokinetics Names Brett Pletcher EVP and Chief Legal Officer
No Data
章允量 :![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
103677010 : noted